A comparative assessment between Globorisk and WHO cardiovascular disease risk scores: a population-based study

Azizallah Dehghan1, Fatemeh Rezaei2, Dagfinn Aune3,4

  • 1Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

Scientific Reports
|August 30, 2023
PubMed

Insights

The World Health Organization (WHO) and Globorisk cardiovascular risk models show good agreement and very strong positive correlation. However, Globorisk classifies more individuals as high-risk, suggesting potential need for model adjustments.

Area of Science:

  • Cardiovascular epidemiology
  • Risk prediction modeling
  • Public health

Background:

  • Cardiovascular disease (CVD) risk prediction models like Globorisk and WHO are crucial for public health interventions.
  • Existing models are often region-specific, necessitating validation in diverse populations.
  • The Fasa cohort study provides a valuable dataset for evaluating CVD risk assessment tools.

Purpose of the Study:

  • To assess the agreement and correlation between the WHO and Globorisk 10-year CVD risk prediction models.
  • To compare laboratory-based and non-laboratory-based versions of these risk models.
  • To evaluate the performance of these models in a specific population (Fasa cohort).

Main Methods:

  • Utilized baseline data from 6796 individuals (aged 40-74) from the Fasa cohort study.
  • Calculated CVD risk scores using WHO and Globorisk models (laboratory-based and non-laboratory-based).
  • Employed kappa statistics for categorical agreement and Pearson correlation/Bland-Altman plots for continuous agreement.

Main Results:

  • Substantial to almost perfect agreement was found between WHO and Globorisk models across risk categories (kappa values 0.73-0.82).
  • Very strong positive correlations (r ≥ 0.95) were observed between laboratory-based and non-laboratory-based scores.
  • Bland-Altman plots indicated systematic differences, with Globorisk identifying more high-risk individuals than WHO.

Conclusions:

  • The WHO and Globorisk models demonstrate good agreement and strong correlation in this population.
  • Systematic differences in risk stratification exist, particularly in higher-risk categories.
  • Further validation and potential modification of risk category cut-points are recommended for these models in this population.

Related Concept Videos

Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
208
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
366
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
155
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
147
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
201
Assessment of the Cardiovascular System II: Inspection01:29

Assessment of the Cardiovascular System II: Inspection

Inspection is the initial step in assessing the cardiovascular system. It involves a detailed visual examination that provides crucial information about a patient's circulatory and cardiac health. This systematic process, conducted from head to toe, helps identify signs of cardiovascular conditions by observing physical appearance, skin and mucous membranes, jugular and carotid pulsations, chest symmetry, and the condition of the extremities.
Head and Neck
287